✦ LIBER ✦

Phase II trial of N-(phosphonacetyl)-l-aspartate (PALA), 5-fluorouracil and recombinant interferon-α-2b in patients with advanced gastric carcinoma

✍ Scribed by S. Wadler; B. Gleissner; R.U. Hilgenfeld; E. Thiel; H. Haynes; R. Kaleya; A. Rozenblit; E.-D. Kreuser

Book ID: 116167865
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 377 KB
Volume: 32
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(96)00035-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of N-phosphonacetyl-L-asp

Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck

✍ Corey J. Langer; David Schaebler; Edward Sauter; Deborah DeMaria; Cheryl Johnson 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Background: 5-fluorouracil (5-fu), as a single agent, produces a 15% response rate in advanced squamous cell carcinoma of the head and neck (scchn). n-phosphonacetyl-l-aspartate (pala) inhibits pyrimidine biosynthesis and increases incorporation of 5-fu metabolites into ribonucleic acid (rna). r

A phase I–II study of N-(phosphonacetyl)

A phase I–II study of N-(phosphonacetyl)-l-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer

✍ Jodrell, D.I; Oster, W; Kerr, D.J; Canney, P.A; Yosef, H; Steward, W.P; Kaye, S. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 687 KB

Phase II clinical trial with 5-fluoroura

Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus

✍ Scott Wadler; Hilda Haynes; Jonathan J. Beitler; Xiaoping Hu; Stanley Fell; Marg 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB 👁 1 views

## Background: Recombinant interferon-alpha (ifn) augments the cytotoxicity of both 5-fluorouracil (5-fu) and cisplatin in vitro. a phase ii study of 5-fu and ifn resulted in response rates of 25-27% in patients with metastatic esophageal carcinoma. ## Methods: A phase ii trial was initiated to d

Double alternate modulation of high dose

Double alternate modulation of high dose fluorouracil (5FU) by interferon alpha (IFNα) and phosphonacetyl-L-aspartic acid (pala) in patients with advanced colorectal cancer (ACC). A multicenter phase II study

✍ Punt, CJA; Burghouts, JThM; Kateman, I; Croles, JJ; Kamm, Y; De Mulder, PHM 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Phase II trial of 5-fluorouracil and rec

Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma

✍ Weh, Hans Josef; Platz, Dieter; Braumann, Dietrich; Buggisch, Peter; Eckardt, Ni 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 505 KB

A Phase II trial of 5-fluorouracil and r

A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma

✍ Richard Pazdur; Jaffer A. Ajani; Rodger Winn; James Bearden; Robert J. Belt; Sus 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 3 views

A Phase I1 clinical trial of the combination of 5-fluorouracil (5-FU) and recombinant alpha-2a-interferon (a-2a-IFN) was conducted in 44 patients. Patients had not received chemotherapy previously and had measurable metastatic gastric carcinoma. 5-FU was administered as a continuous infusion at a do